SEATTLE — JUNE 6, 2018 — Funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, and headquartered at the Fred Hutchinson Cancer Research Center, the HVTN will join study participants, communities and in-country partners to talk about its four large-scale HIV vaccine efficacy clinical trials that are fully enrolled or nearing full enrollment. These large-scale HIV vaccine efficacy clinical trials are underway in the conference host country, South Africa, and in 11 other countries across four continents.
As the world’s largest multi-disciplinary international collaboration facilitating the development of vaccines to prevent HIV, the HVTN is hosting and participating in the following activities, and invites stakeholders and the news media to attend:
Hall 1, 8:30-11:00a.m.
A journey to find a safe and effective HIV prevention response
Hall 8 - 12AB, 7:30-8:30a.m.
The journey to find a safe & effective HIV vaccine
This session, chaired by Professor Glenda Gray and Dr. Simba Takuva, will focus on the HVTN’s journey to find a safe and effective HIV vaccine and cover the topics of study participants and communities, HIV risk in women, partnerships, and updates on large-scale vaccine efficacy studies.
Speakers will include:
News media interviews may be arranged before and after the activities. Please contact Aziel Gangerdine at firstname.lastname@example.org or at 206.384.0945.